Latest Breaking News On - Spanish sarcoma group - Page 1 : comparemela.com

LIXTE Biotechnology Holdings Provides Update on Recent Activities

LIXTE Biotechnology Holdings Provides Update on Recent Activities
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkDana farber cancer instituteFlaurie bermanNetherlands cancer instituteExchange commissionBiotechnology holdings incNational institute of healthNational cancer institutePondelwilkinson incBiotechnology holdings provides update on recent activitiesCompany nasdaqSpanish sarcoma groupSarah cannon research instituteCity of hope cancer centerSecurities exchange

LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations

PASADENA, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a cl.

United statesJohns kovachFlaurie bermanCompany nasdaqLoncode instituteNetherlands cancer instituteBiotechnology holdings incSecurities exchangeSpanish sarcoma group grupo espaCompany quarterly report on formExchange commissionMd anderson cancer centerSarah cannon research institutePondelwilkinson incUniversity of texasCancer center

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable. | June 1, 2023

Kimr tsuchimotoMonopartx linkedinExchange commissionMonopar therapeutics incSpanish sarcoma group grupo espaCurrently enrolling phaseClinical trial designSpanish sarcoma groupGrupo espaPrivate securities litigation reform actFinancial officerMonopar therapeutics inc stock exchangePress releaseChieved mnpr us61023l1089

Monopar Therapeutics (MNPR) Reports Encouraging Camsirubicin Phase 1b Trial Update

Monopar Therapeutics (MNPR) Reports Encouraging Camsirubicin Phase 1b Trial Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Monopartx linkedinKimr tsuchimotoMonopar therapeutics incSpanish sarcoma group grupo espaExchange commissionCurrently enrolling phaseClinical trial designSpanish sarcoma groupGrupo espaPrivate securities litigation reform actFinancial officer

Monopar Therapeutics : Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment - Form 8-K

Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort. | June 1, 2023

Kimr tsuchimotoMonopartx linkedinMonopar therapeutics incSpanish sarcoma group grupo espaExchange commissionCurrently enrolling phaseClinical trial designSpanish sarcoma groupGrupo espaPrivate securities litigation reform actMonopar therapeutics inc stock exchangePress release20 mnpr us61023l1089